Preclinical Studies

Preclinical Study Results of LBI‑1103

Luminus has completed several key preclinical studies, including a maximum tolerated dose (MTD) study, a pharmacokinetics study, and biological activities in a breast tumor xenograft model, and in a pancreatic tumor xenograft model. Results, discussed in the pdf document, show LBI-1103 vs. Taxotere® has significantly greater anti-tumor activity with potentially reduced toxicity.

Luminus Preclinical Study for LBI-1103